For solid tumors, modifying CAR-NK cells through gene editing to continuously secrete IL-15/IL-21 or express chemokine receptors such as CCR2 and CXCR4 significantly strengthens their tumor-specific trafficking and infiltration potential [110]. The gene discussed is IL15; the disease is neoplasm.